1. Introduction {#section0005}
===============

Otitis media (OM) is a very common childhood disease and a major concern for paediatricians. In a prospective, 7-year study performed in the USA, over three quarters (83%) of 498 children who completed the investigation experienced at least one episode of acute OM (AOM) by the age of 3 years and 45% had suffered from at least three episodes [@bib1]. The Centers for Disease Control and Prevention has estimated that OM accounts for more than 20 million physician visits per annum in the USA [@bib2]. Furthermore, in a recent multinational survey, paediatricians reported that they saw at least one patient with OM per day [@bib3].

AOM is often preceded by a viral upper respiratory tract infection (URTI) -- the most common infectious illness in the general population [@bib4], and a very common illness in children. In a prospective, 1-year study following 201 children aged from 6 months to 3 years, a total of 1086 URTIs were recorded, with AOM reported in 341 (31%) children in the course of the viral infection, i.e. 1.7 episodes of AOM per child per year [@bib5].

The underlying microbiology of infectious diseases is known to change in response to environmental factors, such as vaccination and antibiotic consumption. For example, the epidemiology of bacterial meningitis has changed in countries where *Haemophilus influenzae* type b [@bib6], group C meningococcal, and pneumococcal conjugate vaccines have been introduced, with a dramatic reduction in the incidence of bacterial meningitis overall. However, non-vaccine serotypes of *Streptococcus pneumoniae* now account for a more significant proportion of the disease in the countries where the seven-valent pneumococcal conjugate vaccine (PCV7; *Prevnar*™/*Prevenar*™[1](#fn1){ref-type="fn"} ) is widely used [@bib7], [@bib8]. Furthermore, *S. pneumoniae* isolates with reduced susceptibility to penicillin were recovered from human infections in the late 1960s in Australia and New Guinea [@bib9]. Since then, penicillin non-susceptible *S. pneumoniae* strains have spread all over the world and their prevalence has dramatically increased in various countries [@bib10]. Moreover, *S. pneumoniae* accumulated multiple resistance determinants in some strains and serotypes [@bib11], [@bib12], [@bib13], and modified the epidemiological landscape in some regions, including the USA [@bib14]. Although in most regions, penicillin remains active against *S. pneumoniae* despite increased minimal inhibitory concentrations and can be used safely to treat pneumococcal infections other than meningitis, some multiresistant strains have been described in infections such as AOM [@bib15]. A recent report from the USA presented nine clinical failures in AOM due to *S. pneumoniae* resistant to amoxicillin, oral cephalosporins, macrolides, clindamycin, and co-trimoxazole, and required tube placement for drainage and the use of levofloxacin, a drug which is not licensed for paediatric use [@bib16]. In another recent US study, an increased proportion of severe mastoiditis cases was observed, mostly due to multiresistant serotype 19A *S. pneumoniae* [@bib14].

At the beginning of the 20th century, group A *Streptococcus* (GAS) was the most common pathogen leading to complications in AOM, but it is now rare in the Western world. A 'new' triad of AOM pathogens has emerged in the last century -- *S. pneumoniae*, non-encapsulated *H. influenzae* (often called non-typable *H. influenzae* \[NTHi\]), and *Moraxella catarrhalis* -- all of which are commensal bacteria found in the human nasopharynx. This review provides some insight into the microbiology of AOM in an era of antibiotic resistance and pneumococcal conjugate vaccine use.

2. Aetiology of AOM {#section0010}
===================

AOM is a multipathogen disease, and can be caused by a number of different viruses and bacteria. Viruses alone are found in only 20% of cases, while co-infection with bacteria is seen in 65% of cases [@bib17]. Among the viruses, Coronavirus, Respiratory Syncytial Virus, and Adenovirus are most commonly associated with AOM [@bib5]. *S. pneumoniae* and *H. influenzae* are by far the most common bacterial pathogens in AOM, being recovered in up to 80% of cases. *M. catarrhalis* is usually the third most frequent bacterium isolated (3--20%) and GAS makes up 1--5% of cases, although the incidence of GAS infection differs between countries, depending on when the study was performed, and whether severe cases of AOM were included ([Fig. 1](#fig1){ref-type="fig"} ) [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29].Fig. 1Worldwide distribution of the main otopathogens.

3. Clinical presentation and identification of otopathogens {#section0015}
===========================================================

The diagnosis of AOM is difficult as a number of symptoms, for example pain, fever, conjunctivitis, and headache, are shared with other infections of the upper respiratory tract. Furthermore, diagnosis in young children is hampered by the child\'s inability to describe their symptoms and the likelihood that they will be distressed and experiencing pain. For a clinical diagnosis of AOM, the key criteria that should be met are a history of acute onset of signs and symptoms (fever, distinct otalgia that precludes normal activity, or sleep), with signs of middle ear infection (a cloudy, bulging, or clearly immobile eardrum with red colouration of the eardrum and the presence of fluid in the middle ear or otorrhoea) [@bib30], [@bib31].

Some clinical signs have been associated with particular otopathogens (e.g. conjunctivitis is associated with *H. influenzae*, while more severe cases of AOM are more often caused by *S. pneumoniae*) [@bib32], [@bib33], [@bib34]. However, accurate identification of underlying pathogens is not possible purely on clinical grounds. In the large, prospective Finnish trial, severe tympanic membrane findings (bulging tympanic membrane or spontaneous perforation) with concomitant high fever had a 53% positive predictive value and a 79% negative predictive value for a *S. pneumoniae* aetiology of the AOM episode. The presence of a purulent conjunctivitis gave a positive predictive value for *H. influenzae* AOM of 67% with an 86% negative predictive value. No useful predictors were found for *M. catarrhalis* AOM [@bib34].

Even in the absence of definitive clinical signs for the identification of the underlying otopathogen(s), most guidelines do not advocate the systematic use of tympanocentesis, in which fluid is collected from behind the eardrum and analysed to identify the infectious organisms involved and perform antibiotic susceptibility testing. If an antibiotic treatment was to be prescribed, it would be chosen on empirical grounds based on local epidemiological data. However, in selected cases (antibiotic treatment failure and complicated AOM), it is essential to identify the causative otopathogen accurately and determine its antibiotic susceptibility. Tympanocentesis will, therefore, be recommended in order to ensure the most effective treatment course [@bib31], [@bib35], [@bib36].

4. Incidence of AOM -- microbiological patterns {#section0020}
===============================================

All-cause AOM incidence peaks between the ages of 6 and 12 months, with one study reporting a peak incidence at 12 months of 17.8 AOM events/100 child months ([Fig. 2](#fig2){ref-type="fig"} ) [@bib23]. In this study, NTHi showed a distinct pattern of incidence compared with *S. pneumoniae* and *M. catarrhalis*. There was an increase in the incidence of NTHi AOM after the age of 15 months, peaking at 19 months (6.4 AOM events/100 child months). Moreover, *H. influenzae* was associated with recurrent AOM. It was recovered in middle ear fluid (MEF) in 12% of first AOM episodes compared with 25% of all subsequent OM episodes, and when only the first AOM episodes were considered, no peak in the incidence of *H. influenzae* AOM could be demonstrated in children over 1 year of age.Fig. 2Age-specific incidence rates of AOM [@bib23]. Reproduced with permission from Kilpi et al. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J 2001;20:654-62.

5. Complications arising from AOM -- impact of otopathogens {#section0025}
===========================================================

Despite the use and availability of antibiotics and appropriate medical access, AOM can often lead to recurrences and, in rare cases, severe intratemporal (facial paralysis, labyrinthitis, and acute petrosistis, which are extremely uncommon) and intracranial complications, such as mastoiditis, meningitis, intracranial abscesses, and sinus thrombosis. Although mastoiditis has become infrequent in industrialized countries (incidences from 0.3 to 6/100,000 child-year) [@bib37], [@bib38], [@bib39], it is still a common belief that antibiotic treatment should be prescribed in AOM to prevent its occurrence. The prevention of mastoiditis by systematic antibiotic treatment of AOM has never been established [@bib40], [@bib41]. Many factors can account for variations in the incidence of mastoiditis in different countries: socio-economic and living conditions, antibiotic prescribing rates, exhaustiveness of the epidemiological surveillance systems, and differences in complication rates by pathogens [@bib29], [@bib38], [@bib42]. Indeed, not all bacterial otopathogens have the same propensity to cause complications of AOM. GAS is associated with the most frequent and severe complications, such as mastoiditis ([Table 1](#tbl1){ref-type="table"} ), while severe complications of *H. influenzae* are uncommon and those of *M. catarrhalis* infection are rare [@bib29].Table 1The risk for development of mastoiditis following AOM caused by different bacterial otopathogens [@bib29].Bacterial otopathogenIncidenceCases of mastoiditis/1000 episodes of AOM (95% CI)Group A *Streptococcus*4/34611.6 (3.2--29.3)*Streptococcus pneumoniae*8/36512.2 (0.9--4.3)*Haemophilus influenzae*1/39990.3 (0.0--1.4)*Moraxella catarrhalis*0/3940.0 (0.0--3.0)

As previously discussed, evidence suggests that *S. pneumoniae* is more common in severe episodes of OM [@bib33], while NTHi is more commonly associated with recurrent OM (ROM) ([Fig. 2](#fig2){ref-type="fig"}) [@bib23], [@bib43]. One recent study assessed the underlying microbiology of ROM (defined as three acute episodes in the previous 6 months or four in the past 12 months) and AOM treatment failure (defined as persisting signs and symptoms of AOM after ≥48 h of antibiotic therapy or within 30 days of completing an antibiotic treatment course) in US children following the widespread introduction of PCV7 in 2000 [@bib43]. Although there was a slight increase in the proportion of *S. pneumoniae* isolates present during the 2005--2006 season, *H. influenzae* was the most frequently isolated pathogen (51% of all isolates across three respiratory seasons, 2003--2006) in this difficult-to-treat patient group during a time of increasing and widespread use of PCV7 ([Fig. 3](#fig3){ref-type="fig"} ).Fig. 3AOM pathogens identified in the PCV7 era using tympanocentesis in US children failing initial antibiotic therapy or with recurrent infection [@bib43]. Pichichero et al. Clin Pediatr (Phila); June 16, 2008 \[Epub ahead of print\], © 2008 by SAGE. Reprinted by permission of SAGE publications.

6. Otopathogens and resistance to treatment {#section0030}
===========================================

Difficulties encountered in the treatment of OM are not only due to the existence of antibiotic resistance in otopathogens, but are also attributable to the biofilm nature of bacterial OM infections.

6.1. Biofilms {#section0035}
-------------

In natural environments, the majority of bacteria exist as a biofilm (a structured community of microorganisms embedded within a polymeric matrix that is attached to an inert or living surface) rather than in a planktonic state. In contrast to planktonic bacteria, biofilm bacteria are characterized by slow rates of cell division and a tolerance to very high concentrations of antibiotics. Biofilm infections are, therefore, difficult to treat effectively with currently available antibiotic agents, which rely on the rapid metabolic and divisional rates of planktonic bacteria for their mode of action.

The presence of bacterial biofilms in OM was first suspected owing to the persistence of infection despite treatment with antibiotics and the absence of positive cell culture specimens. Definitive evidence for the biofilm nature of OM has been provided by a number of studies. For example, one study used polymerase chain reaction techniques to detect *H. influenzae* DNA and mRNA in MEF from children with chronic OM with effusion. The presence of the short-lived mRNA molecules, even in the absence of positive culture specimens, indicated the presence of viable bacteria in these specimens [@bib44]. Additionally, the three major bacterial pathogens of OM have been proven to form biofilms *in vitro* and *in vivo* [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], while one study has reported the direct detection of bacterial biofilms on middle ear mucosa biopsies from children with chronic OM [@bib50].

6.2. Antibiotic resistance {#section0040}
--------------------------

Antibiotic use results in the selection of strains resistant to antibiotics. This was demonstrated *in vitro* for *S. pneumoniae* by Alexander Fleming shortly after he discovered penicillin [@bib51]. More recently, the correlation between antibiotic consumption and resistance was demonstrated in a European study comprising 26 countries. Outpatient antibiotic use was correlated with resistance for all antibiotic--pathogen combinations, and more specifically for *S. pneumoniae* [@bib52]. The nasopharynx constitutes a wide reservoir where resistant bacteria (*S. pneumoniae* but also *Streptococcus viridans*, *H. influenzae*, and *M. catarrhalis*) can easily be selected whenever antibiotic selective pressure is applied [@bib53].

Antibiotic resistance in *S. pneumoniae* and *H. influenzae* has become a major public health issue and a European Union priority for research and action. It is expected that the prevalence of chronic obstructive pulmonary disease will increase in the coming years in Europe, and both *S. pneumoniae* and *H. influenzae* have major infectious roles for this condition [@bib54]. Similarly, the World Health Organization (WHO) has set antimicrobial resistance containment as a research priority, particularly regarding *S. pneumoniae* [@bib55].

All three major otopathogens cause antibiotic resistance concerns. Penicillin and multidrug resistance in *S. pneumoniae* has already been described above. In Europe, dual erythromycin and penicillin non-susceptibility varies widely between countries, from less than 1% to more than 25% [@bib56]. While amoxicillin resistance in *M. catarrhalis* is universally seen in approximately 90% of the strains, it is still a limited occurrence in NTHi (a mean of 13% β-lactamase production in one international study) [@bib57]. However, some regions, such as France, the USA, Japan, and other Southern Asian regions have high rates of amoxicillin resistance in NTHi [@bib58], [@bib59]. Several mechanisms cause this resistance, the most common being β-lactamase production, which is detected in most laboratories. However, other resistance mechanisms are increasingly being described in France and Japan, which confer additional resistance to amoxicillin-clavulanate, cefuroxime, and sometimes to third-generation cephalosporins, and which are usually not investigated in routine microbiology [@bib59], [@bib60]. In a recent study conducted in Japan, only 44% of the NTHi strains isolated from children with URTIs were amoxicillin susceptible and 4% were β-lactamase producers; the others were also resistant to amoxicillin-clavulanate and to a various degree to cephalosporins [@bib61].

7. Impact of vaccination on otopathogens {#section0045}
========================================

The introduction of conjugate vaccines that impact on the commensal flora creates 'epidemiological niches' for alternative potential pathogens that are not included in the vaccine. The introduction of PCV7 in the USA resulted in rapid shifts in the microbiology of OM [@bib18], [@bib43], [@bib62], [@bib63]. PCV7 vaccination was followed by rapid replacement with non-vaccine *S. pneumoniae* serotypes in the nasopharynx of vaccinated children and their siblings and, as a result, the proportion of AOM caused by vaccine serotypes has fallen and disease caused by non-vaccine serotypes and other pathogens, such as NTHi, has risen. For example, in one US study, significant increases in the percentage of AOM cases due to non-PCV7 pneumococcal serogroups occurred between 1999 and 2002 (from 12% to 32%, respectively; *p*  \< 0.01). However, no decline was observed in the penicillin non-susceptible *S. pneumoniae* strains [@bib63]. As mentioned previously, multidrug-resistant replacement serotypes may arise [@bib16], stressing the need for reduced antibiotic prescribing in order to maximize the benefits of the vaccine in eliminating the most prevalent antibiotic-resistant serotypes. Additionally, the trend for an increase in persistent AOM and AOM treatment failure attributable to *H. influenzae* observed from 2001 to 2003 in a single US study centre [@bib62] was also reported in three US centres for the period 2003--2006 [@bib43].

8. Conclusions {#section0050}
==============

OM is a common disease that affects approximately three quarters of children before their third birthday. Currently, *S. pneumoniae* and NTHi are responsible for approximately 80% of all bacterial AOM cases, with *S. pneumoniae* generally causing more severe episodes, and NTHi responsible for recurrent episodes.

The underlying microbiology of OM, which is inherently linked to the nasopharyngeal commensal flora, is changing over time in response to various selective pressures, such as vaccine use and antibiotic consumption. Consequently, continuous monitoring of the changes in underlying OM microbiology is required in order to provide the most effective preventative and treatment strategies for combating this common and distressing childhood disease.
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